The denial of the continued listing request by Nasdaq and the subsequent suspension of trading on June 17 are significant negative events for ThermoGenesis. The company's stock price has already dropped 41%, and the lack of an appeal plan further solidifies the negative outlook. The stock is expected to move to the Over-the-Counter Market, which typically has less liquidity and visibility, potentially leading to further declines.